Differences in Thromboembolic Complications Between Paroxysmal and Persistent Atrial Fibrillation Patients Following Electrical Cardioversion (From the ENSURE-AF Study)

Differences in Thromboembolic Complications Between Paroxysmal and Persistent Atrial Fibrillation Patients Following Electrical Cardioversion (From the ENSURE-AF Study)

It is unclear if patients with paroxysmal atrial fibrillation (AF) and persistent AF have different outcomes following electrical cardioversion (ECV). ENSURE-AF—a multicenter, prospective, randomized, open-label, blinded-endpoint evaluation trial—compared once-daily edoxaban 60 mg with enoxaparin–wa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of cardiology 2020-09, Vol.131, p.27-32
Hauptverfasser: Goette, Andreas, Lip, Gregory Y.H., Jin, James, Heidbuchel, Hein, Cohen, Aron-Ariel, Ezekowitz, Michael, Merino, Jose Luis
Format: Artikel
Sprache:eng
Schlagworte:
Anticoagulants
Cardiac arrhythmia
Cardioversion
Cerebral infarction
Complications
Congestive heart failure
Conversion
Drug dosages
Echocardiography
Embolisms
Fibrillation
Heart attacks
Heart failure
Hypertension
Myocardial infarction
Regression analysis
Stroke
Thromboembolism
Warfarin
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:It is unclear if patients with paroxysmal atrial fibrillation (AF) and persistent AF have different outcomes following electrical cardioversion (ECV). ENSURE-AF—a multicenter, prospective, randomized, open-label, blinded-endpoint evaluation trial—compared once-daily edoxaban 60 mg with enoxaparin–warfarin in 2,199 subjects undergoing ECV of nonvalvular AF (NCT02072434). Patients received ≥3 weeks of proper anticoagulation or transesophageal echocardiogram before ECV paroxysmal AF was defined as AF with spontaneous conversion of duration of
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2020.06.046